Sharma Samin K, Rao Ravinder S, Chopra Manik, Sonawane Anmol, Jose John, Sengottuvelu Gunasekaran
Director of Clinical and Interventional Cardiology and Dean of International Clinical Affiliations, Mount Sinai Health System, NY, USA.
Department of Cardiology, Eternal Heart Care Centre & Research Institute Pvt. Ltd., Jaipur, Rajasthan 302017, India.
Future Cardiol. 2021 Jan;17(1):73-80. doi: 10.2217/fca-2020-0020. Epub 2020 Jul 6.
The transcatheter aortic valve replacement (TAVR) is an established treatment for patients with severe symptomatic aortic stenosis (AS) at prohibitive risk for surgery. It is an alternative treatment to surgical aortic valve replacement in patients with AS at intermediate- and high-surgical risk. Although regulatory authorities extend the indications of TAVR to treat patients at low-surgical risk, the limitations of earlier-generation transcatheter heart valve (THV) systems accelerate the development of improved newer generation of THV systems. Myval™ THV (Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India) is a newer-generation, balloon-expandable TAVR system with features that facilitate accurate positioning of the bioprosthetic valve and favorable procedural and clinical outcomes. This review summarizes existing preclinical and clinical data on Myval THV for the intervention of symptomatic native AS and lays out the plan for future research program.
经导管主动脉瓣置换术（TAVR）是一种针对手术风险极高的重度症状性主动脉瓣狭窄（AS）患者的既定治疗方法。它是中高手术风险的AS患者进行外科主动脉瓣置换术的替代治疗方法。尽管监管机构扩大了TAVR的适应症以治疗低手术风险患者，但早期经导管心脏瓣膜（THV）系统的局限性加速了新一代改良THV系统的开发。Myval™ THV（印度古吉拉特邦瓦皮市Meril生命科学私人有限公司）是新一代球囊扩张式TAVR系统，具有有助于生物人工瓣膜准确定位以及良好手术和临床结果的特点。本综述总结了关于Myval THV用于干预症状性原发性AS的现有临床前和临床数据，并制定了未来研究计划。
